High-throughput autoantibody analysis in malignant pleural effusion and tuberculosis pleural effusion

3Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Background:Malignant pleural effusion (MPE) and tuberculosis pleural effusion (TPE) are 2 kinds of common pleural diseases. Finding efficient and accurate biomarkers to distinguish the 2 is of benefit to basic and clinical research. In the present study, we carried out the first high-throughput autoantibody chip to screen the beneficial biomarker with samples of MPE and TPE and the corresponding serum.Methods:We collected pleural effusion and serum of patients with MPE (n=10) and TPE (n=10) who had been in Beijing Chao-Yang hospital from June 2013 to August 2014. Using RayBio Human Protein Array-G2 to measure the concentration of 487 defined autoantibodies.Results:Fold changes of Bcl-2-like protein 11 (BIM) autoantibody in MPE-serum/TPE-serum and MPE/TPE groups were 10 (P=.019) and 6 (P=.001); for decorin autoantibody, MPE-serum/TPE-serum ratio was 0.6 (P=.029), and MPE/TPE ratio was 0.3 (P

Cite

CITATION STYLE

APA

Yi, F., Zhang, X., & Ding, J. (2019). High-throughput autoantibody analysis in malignant pleural effusion and tuberculosis pleural effusion. Medicine (United States), 98(38). https://doi.org/10.1097/MD.0000000000017253

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free